Asia300

PT Kalbe Farma Tbk

Indonesia

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Aug 18, 2017
Prev close: 1,750
Aug 18, 2017
Market cap:
Market cap(USD):
82,031.47B
6,139.16M
Shares: 46,875.12M

Currency in IDR

Company profile

Market(Ticker): JKT(KLBF)
Sector:
Industry:
Health Technology
Pharmaceuticals: Other
Full time employees: 12,736

Business summary

PT Kalbe Farma Tbk engages in the development, production, distribution, and trade of pharmaceutical products. It operates through the following segments: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical segment offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores throughout Indonesia. The Consumer Health segment provides over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals segment sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistics segment maintains distribution of the company's and third party principal's products across Indonesia, and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.

Company background

Indonesia's Kalbe Farma is one of Southeast Asia's largest pharmaceutical companies. It has a diverse lineup of products, ranging from prescription medicine to vitamins to energy drinks.

The company has its own distribution network that carries products to a large number of retail outlets. It also distributes products for major foreign pharmaceutical companies, including Astellas Pharma of Japan and Baxter of the U.S.

Kalbe Farma was launched out of a garage by Boenjamin Setiawan, who is now in his 80s, and his brothers. Setiawan has left the board of directors and now serves as honorary chairman. His niece, Bernadette Ruth Irawati Setiady, has served as president since 2008. The group of founders holds a significant stake in the company.

Kalbe Farma has been expanding its consumer sector, acquiring local health-drink producer Hale International in 2012. The company exports some of its products to neighboring countries.

In the news

Financial highlights

Dec 2016

  • Local currency
  • US Dollar
Revenue 19,374.23B
Gross profit 9,258.50B
Operating income 2,976.16B
Income before tax 3,091.18B
Net income 2,299.73B
EBITDA 3,416.92B
Diluted EPS 49.06
Dividends per share 22
Total assets 15,226.00B
Total liabilities 2,762.16B
Total equity 11,909.26B
Operating cash flow 2,233.38B

Currency in IDR

Revenue 1,456.66M
Gross profit 696.10M
Operating income 223.76M
Income before tax 232.41M
Net income 172.90M
EBITDA 256.90M
Diluted EPS 0.00
Dividends per share 0.00
Total assets 1,130.15M
Total liabilities 205.02M
Total equity 883.96M
Operating cash flow 167.91M

Currency in USD

Valuation measures

Dec 2016

PER 30.88
ROA 15.90%
ROE 20.55%
Operating margin 15.36%
Profit margin 11.87%

Key executive

  • President Director: Bernadette Ruth Setiady
  • Head-Corporate Finance, Accounting & Tax: Bernadus Karmin Winata
  • Head-Corporate Information Technology & System: Dino Bramanto
  • Director: Bujung Nugroho
  • Director: Ongkie Tedjasurja

Share holders

  • PT Gira Sole Prima(10.1%)
  • PT Santa Seha Sanadi(9.6%)
  • PT Diptanala Bahana(9.4%)
  • PT Lucasta Murni Cemerlang(9.4%)
  • PT Ladang Ira Panen(9.2%)
  • PT Bina Arta Charisma(8.5%)
  • First State Investment Management (UK) Ltd.(1.6%)
  • PT Schroder Investment Management Indonesia(1.4%)
  • The Vanguard Group, Inc.(1.3%)
  • BlackRock Fund Advisors(1.2%)

Address

  • Website: http://www.kalbe.co.id
  • Address: Gedung KALBE, Jalan Let. Jend. Suprapto Kavling 4, Jakarta, 10510, Indonesia
  • Phone: +62.21.4287.3888

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.